Fly News Breaks for September 4, 2018
Sep 4, 2018 | 08:23 EDT
Argus analyst Jasper Hellweg kept his Hold rating on Baxter but said he is looking for a "non-fundamental" pullback in the stock price to high $60's to justify a potential upgrade. The analyst cites the company's "substantially improved" profitability in recent quarters, noting that its new long-term financial goals suggest "continued margin and profit growth". Hellweg is also positive on Baxter's emphasizing geographic expansion and partnerships in drug distribution and development of generics, and also notes that its two main segments - Renal and Hospital Products - could be bolstered by acquisitions. The analyst further states that Baxter's 19% dividend increase indicates confidence in its business prospects.
News For BAX From the Last 2 Days
Mar 19, 2019 | 06:16 EDT
Baxter and bioMerieux announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury, or AKI. The announcement was made at the International Symposium on Intensive Care and Emergency Medicine, or ISICEM. AKI is a sudden decrease in kidney function over a period of hours to days, often the result of illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the blood that, if left untreated, may lead to death. The most severe stage of AKI requires renal replacement therapy to replace the function of the kidneys. AKI is an increasingly common complication of acute illnesses in intensive care units and hospitals and early diagnosis is important. Additional details about the agreement were not disclosed.